Kenmerk
Migraine
Migraine is a chronic neurological disorder characterized by episodic attacks of headache and associated symptoms.
Samenvatting
- Ook bekend als
- Intermittent migraine headaches, Migraine headache, Migraine headaches
- Lichaamssysteem
- Abnormality of the nervous system
ReferentiegenoomGRCh38hg38
Posities op gen- en variantpagina's volgen deze keuze, in deze browser.
Read the genes linked to Migraine, and the rest of your genome, with one test.
Vanaf $ 449Gratis verzending · Resultaten binnen 6–8 weken
Mijn Genome Test bestellen157 genen gekoppeld aan Migraine
Veranderingen in deze genen veroorzaken zeldzame aandoeningen waarbij Migraine voorkomt. De meeste mensen met dit kenmerk hebben geen van die aandoeningen, en een gen op deze lijst zegt niets over het eigen genoom van iemand.
| Gen | Hoe vaak het voorkomt | Aandoeningen |
|---|---|---|
| AMACRalpha-methylacyl-CoA racemase | Altijd | In 2 aandoeningen |
| ATP1A2ATPase Na+/K+ transporting subunit alpha 2 | Altijd | In 1 aandoening |
| CACNA1Acalcium voltage-gated channel subunit alpha1 A | Altijd | In 4 aandoeningen |
| CSNK1Dcasein kinase 1 delta | Altijd | In 1 aandoening |
| CTSAcathepsin A | Altijd | In 1 aandoening |
| JPH1junctophilin 1 | Altijd | In 1 aandoening |
| LRRC7leucine rich repeat containing 7 | Altijd | In 1 aandoening |
| NOTCH3notch receptor 3 | Altijd | In 3 aandoeningen |
| PEX11Bperoxisomal biogenesis factor 11 beta | Altijd | In 1 aandoening |
| RAB3ARAB3A, member RAS oncogene family | Altijd | In 1 aandoening |
| ADA2adenosine deaminase 2 | Heel vaak (80–99%) | In 1 aandoening |
| APPamyloid beta precursor protein | Heel vaak (80–99%) | In 2 aandoeningen |
| C4Acomplement C4A (Chido/Rodgers blood group) | Heel vaak (80–99%) | In 1 aandoening |
| CCR1C-C motif chemokine receptor 1 | Heel vaak (80–99%) | In 1 aandoening |
| CLTRNcollectrin, amino acid transport regulator | Heel vaak (80–99%) | In 1 aandoening |
| COL5A1collagen type V alpha 1 chain | Heel vaak (80–99%) | In 1 aandoening |
| ERAP1endoplasmic reticulum aminopeptidase 1 | Heel vaak (80–99%) | In 1 aandoening |
| FASFas cell surface death receptor | Heel vaak (80–99%) | In 1 aandoening |
| HLA-Bmajor histocompatibility complex, class I, B | Heel vaak (80–99%) | In 2 aandoeningen |
| IFNGR1interferon gamma receptor 1 | Heel vaak (80–99%) | In 1 aandoening |
| IL10interleukin 10 | Heel vaak (80–99%) | In 1 aandoening |
| IL12Ainterleukin 12A | Heel vaak (80–99%) | In 1 aandoening |
| IL12A-AS1IL12A antisense RNA 1 | Heel vaak (80–99%) | In 1 aandoening |
| IL23Rinterleukin 23 receptor | Heel vaak (80–99%) | In 1 aandoening |
| KLRC4killer cell lectin like receptor C4 | Heel vaak (80–99%) | In 1 aandoening |
| MEFVMEFV innate immunity regulator, pyrin | Heel vaak (80–99%) | In 1 aandoening |
| MT-CO1mitochondrially encoded cytochrome c oxidase I | Heel vaak (80–99%) | In 2 aandoeningen |
| MT-CO2mitochondrially encoded cytochrome c oxidase II | Heel vaak (80–99%) | In 2 aandoeningen |
| MT-CO3mitochondrially encoded cytochrome c oxidase III | Heel vaak (80–99%) | In 2 aandoeningen |
| MT-ND1mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1 | Heel vaak (80–99%) | In 2 aandoeningen |
| MT-ND4mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4 | Heel vaak (80–99%) | In 1 aandoening |
| MT-ND5mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5 | Heel vaak (80–99%) | In 2 aandoeningen |
| MT-ND6mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6 | Heel vaak (80–99%) | In 2 aandoeningen |
| MT-TFmitochondrially encoded tRNA-Phe (UUU/C) | Heel vaak (80–99%) | In 2 aandoeningen |
| MT-THmitochondrially encoded tRNA-His (CAU/C) | Heel vaak (80–99%) | In 2 aandoeningen |
| MT-TL1mitochondrially encoded tRNA-Leu (UUA/G) 1 | Heel vaak (80–99%) | In 2 aandoeningen |
| MT-TQmitochondrially encoded tRNA-Gln (CAA/G) | Heel vaak (80–99%) | In 2 aandoeningen |
| MT-TS1mitochondrially encoded tRNA-Ser (UCN) 1 | Heel vaak (80–99%) | In 2 aandoeningen |
| MT-TS2mitochondrially encoded tRNA-Ser (AGU/C) 2 | Heel vaak (80–99%) | In 2 aandoeningen |
| MT-TWmitochondrially encoded tRNA-Trp (UGA/G) | Heel vaak (80–99%) | In 2 aandoeningen |
Toon nog 117 genen
| Gen | Hoe vaak het voorkomt | Aandoeningen |
|---|---|---|
| NLRP3NLR family pyrin domain containing 3 | Heel vaak (80–99%) | In 1 aandoening |
| SLC6A19solute carrier family 6 member 19 | Heel vaak (80–99%) | In 1 aandoening |
| STAT4signal transducer and activator of transcription 4 | Heel vaak (80–99%) | In 1 aandoening |
| TLR4toll like receptor 4 | Heel vaak (80–99%) | In 1 aandoening |
| UBAC2UBA domain containing 2 | Heel vaak (80–99%) | In 1 aandoening |
| ACVRL1activin A receptor like type 1 | Vaak (30–79%) | In 2 aandoeningen |
| ADAMTS3ADAM metallopeptidase with thrombospondin type 1 motif 3 | Vaak (30–79%) | In 1 aandoening |
| ADAMTSL1ADAMTS like 1 | Vaak (30–79%) | In 1 aandoening |
| AIPAHR interacting HSP90 co-chaperone | Vaak (30–79%) | In 1 aandoening |
| ALPK1alpha kinase 1 | Vaak (30–79%) | In 1 aandoening |
| ATMATM serine/threonine kinase | Vaak (30–79%) | In 1 aandoening |
| BMPR1Abone morphogenetic protein receptor type 1A | Vaak (30–79%) | In 1 aandoening |
| BRCA2BRCA2 DNA repair associated | Vaak (30–79%) | In 1 aandoening |
| CALRcalreticulin | Vaak (30–79%) | In 1 aandoening |
| CHEK2checkpoint kinase 2 | Vaak (30–79%) | In 1 aandoening |
| CST3cystatin C | Vaak (30–79%) | In 1 aandoening |
| ENGendoglin | Vaak (30–79%) | In 2 aandoeningen |
| EPCAMepithelial cell adhesion molecule | Vaak (30–79%) | In 1 aandoening |
| GATA2GATA binding protein 2 | Vaak (30–79%) | In 1 aandoening |
| GDF2growth differentiation factor 2 | Vaak (30–79%) | In 1 aandoening |
| GPR101G protein-coupled receptor 101 | Vaak (30–79%) | In 1 aandoening |
| GUK1guanylate kinase 1 | Vaak (30–79%) | In 1 aandoening |
| IL12Binterleukin 12B | Vaak (30–79%) | In 1 aandoening |
| JAK2Janus kinase 2 | Vaak (30–79%) | In 1 aandoening |
| KRASKRas proto-oncogene, GTPase | Vaak (30–79%) | In 1 aandoening |
| MLH1mutL homolog 1 | Vaak (30–79%) | In 1 aandoening |
| MLXMAX dimerization protein MLX | Vaak (30–79%) | In 1 aandoening |
| MPLMPL proto-oncogene, thrombopoietin receptor | Vaak (30–79%) | In 1 aandoening |
| MRPL39mitochondrial ribosomal protein L39 | Vaak (30–79%) | In 1 aandoening |
| MSH2mutS homolog 2 | Vaak (30–79%) | In 1 aandoening |
| MSH6mutS homolog 6 | Vaak (30–79%) | In 1 aandoening |
| MUTYHmutY DNA glycosylase | Vaak (30–79%) | In 1 aandoening |
| MVKmevalonate kinase | Vaak (30–79%) | In 1 aandoening |
| NAA60N-alpha-acetyltransferase 60, NatF catalytic subunit | Vaak (30–79%) | In 1 aandoening |
| NF1neurofibromin 1 | Vaak (30–79%) | In 1 aandoening |
| NPATnuclear protein, coactivator of histone transcription | Vaak (30–79%) | In 1 aandoening |
| PGK1phosphoglycerate kinase 1 | Vaak (30–79%) | In 2 aandoeningen |
| PIK3CAphosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | Vaak (30–79%) | In 1 aandoening |
| PMS1PMS1 homolog 1, mismatch repair system component | Vaak (30–79%) | In 1 aandoening |
| PMS2PMS1 homolog 2, mismatch repair system component | Vaak (30–79%) | In 1 aandoening |
| POLD1DNA polymerase delta 1, catalytic subunit | Vaak (30–79%) | In 1 aandoening |
| POLEDNA polymerase epsilon, catalytic subunit | Vaak (30–79%) | In 1 aandoening |
| POLGDNA polymerase gamma, catalytic subunit | Vaak (30–79%) | In 4 aandoeningen |
| RPS20ribosomal protein S20 | Vaak (30–79%) | In 1 aandoening |
| SEMA4Asemaphorin 4A | Vaak (30–79%) | In 1 aandoening |
| SH2B3SH2B adaptor protein 3 | Vaak (30–79%) | In 1 aandoening |
| SMAD2SMAD family member 2 | Vaak (30–79%) | In 1 aandoening |
| SMAD3SMAD family member 3 | Vaak (30–79%) | In 2 aandoeningen |
| SMAD4SMAD family member 4 | Vaak (30–79%) | In 1 aandoening |
| SMARCAL1SNF2 related chromatin remodeling annealing helicase 1 | Vaak (30–79%) | In 1 aandoening |
| SMARCB1SWI/SNF related BAF chromatin remodeling complex subunit B1 | Vaak (30–79%) | In 1 aandoening |
| SPOPspeckle type BTB/POZ protein | Vaak (30–79%) | In 1 aandoening |
| SQORsulfide quinone oxidoreductase | Vaak (30–79%) | In 1 aandoening |
| STARD7StAR related lipid transfer domain containing 7 | Vaak (30–79%) | In 1 aandoening |
| STIM1stromal interaction molecule 1 | Vaak (30–79%) | In 1 aandoening |
| SUFUSUFU negative regulator of hedgehog signaling | Vaak (30–79%) | In 1 aandoening |
| TET2tet methylcytosine dioxygenase 2 | Vaak (30–79%) | In 1 aandoening |
| TGFBR2transforming growth factor beta receptor 2 | Vaak (30–79%) | In 1 aandoening |
| TP53tumor protein p53 | Vaak (30–79%) | In 1 aandoening |
| TREX1three prime repair exonuclease 1 | Vaak (30–79%) | In 2 aandoeningen |
| ZFTAzinc finger translocation associated | Vaak (30–79%) | In 1 aandoening |
| ACSF3acyl-CoA synthetase family member 3 | Soms (5–29%) | In 1 aandoening |
| COPB1coat protein complex I subunit beta 1 | Soms (5–29%) | In 1 aandoening |
| CTSHcathepsin H | Soms (5–29%) | In 1 aandoening |
| FGFR2fibroblast growth factor receptor 2 | Soms (5–29%) | In 1 aandoening |
| FGFR3fibroblast growth factor receptor 3 | Soms (5–29%) | In 2 aandoeningen |
| FRMD5FERM domain containing 5 | Soms (5–29%) | In 1 aandoening |
| GABRG2gamma-aminobutyric acid type A receptor subunit gamma2 | Soms (5–29%) | In 1 aandoening |
| GRIN2Aglutamate ionotropic receptor NMDA type subunit 2A | Soms (5–29%) | In 1 aandoening |
| HCRThypocretin neuropeptide precursor | Soms (5–29%) | In 1 aandoening |
| HLA-DQB1major histocompatibility complex, class II, DQ beta 1 | Soms (5–29%) | In 1 aandoening |
| HLA-DRB1major histocompatibility complex, class II, DR beta 1 | Soms (5–29%) | In 1 aandoening |
| JAG1jagged canonical Notch ligand 1 | Soms (5–29%) | In 1 aandoening |
| KCNA1potassium voltage-gated channel subfamily A member 1 | Soms (5–29%) | In 1 aandoening |
| KCNJ10potassium inwardly rectifying channel subfamily J member 10 | Soms (5–29%) | In 1 aandoening |
| MOGmyelin oligodendrocyte glycoprotein | Soms (5–29%) | In 1 aandoening |
| MYD88MYD88 innate immune signal transduction adaptor | Soms (5–29%) | In 1 aandoening |
| MYORGmyogenesis regulating glycosidase | Soms (5–29%) | In 1 aandoening |
| NDPnorrin cystine knot growth factor NDP | Soms (5–29%) | In 1 aandoening |
| NFIXnuclear factor I X | Soms (5–29%) | In 1 aandoening |
| P2RY11purinergic receptor P2Y11 | Soms (5–29%) | In 1 aandoening |
| PDGFBplatelet derived growth factor subunit B | Soms (5–29%) | In 1 aandoening |
| PDGFRBplatelet derived growth factor receptor beta | Soms (5–29%) | In 1 aandoening |
| PLAAT3phospholipase A and acyltransferase 3 | Soms (5–29%) | In 1 aandoening |
| PRORPprotein only RNase P catalytic subunit | Soms (5–29%) | In 1 aandoening |
| PRRT2proline rich transmembrane protein 2 | Soms (5–29%) | In 2 aandoeningen |
| RNASEH1ribonuclease H1 | Soms (5–29%) | In 1 aandoening |
| RRM2Bribonucleotide reductase regulatory TP53 inducible subunit M2B | Soms (5–29%) | In 2 aandoeningen |
| SH2B1SH2B adaptor protein 1 | Soms (5–29%) | In 1 aandoening |
| SLC1A3solute carrier family 1 member 3 | Soms (5–29%) | In 2 aandoeningen |
| SLC2A1solute carrier family 2 member 1 | Soms (5–29%) | In 2 aandoeningen |
| SRPX2sushi repeat containing protein X-linked 2 | Soms (5–29%) | In 1 aandoening |
| TNFRSF1ATNF receptor superfamily member 1A | Soms (5–29%) | In 1 aandoening |
| TNFSF4TNF superfamily member 4 | Soms (5–29%) | In 1 aandoening |
| TWIST1twist family bHLH transcription factor 1 | Soms (5–29%) | In 1 aandoening |
| TWNKtwinkle mtDNA helicase | Soms (5–29%) | In 4 aandoeningen |
| ZNF365zinc finger protein 365 | Soms (5–29%) | In 1 aandoening |
| DNM1Ldynamin 1L | Zelden (1–4%) | In 1 aandoening |
| GP1BAglycoprotein Ib platelet subunit alpha | Zelden (1–4%) | In 1 aandoening |
| GP1BBglycoprotein Ib platelet subunit beta | Zelden (1–4%) | In 1 aandoening |
| GP9glycoprotein IX platelet | Zelden (1–4%) | In 1 aandoening |
| LGI1leucine rich glioma inactivated 1 | Zelden (1–4%) | In 1 aandoening |
| MICAL1microtubule associated monooxygenase, calponin and LIM domain containing 1 | Zelden (1–4%) | In 1 aandoening |
| NOP56NOP56 ribonucleoprotein | Zelden (1–4%) | In 1 aandoening |
| OPA1OPA1 mitochondrial dynamin like GTPase | Zelden (1–4%) | In 2 aandoeningen |
| POLG2DNA polymerase gamma 2, accessory subunit | Zelden (1–4%) | In 1 aandoening |
| PPIBpeptidylprolyl isomerase B | Zelden (1–4%) | In 1 aandoening |
| RELNreelin | Zelden (1–4%) | In 1 aandoening |
| SLC25A4solute carrier family 25 member 4 | Zelden (1–4%) | In 1 aandoening |
| ANO1anoctamin 1 | Niet vastgelegd | In 1 aandoening |
| COL4A1collagen type IV alpha 1 chain | Niet vastgelegd | In 1 aandoening |
| HTR1A5-hydroxytryptamine receptor 1A | Niet vastgelegd | In 1 aandoening |
| MT-CYBmitochondrially encoded cytochrome b | Niet vastgelegd | In 1 aandoening |
| MT-TCmitochondrially encoded tRNA-Cys (UGU/C) | Niet vastgelegd | In 1 aandoening |
| MT-TKmitochondrially encoded tRNA-Lys (AAA/G) | Niet vastgelegd | In 1 aandoening |
| MT-TL2mitochondrially encoded tRNA-Leu (CUN) 2 | Niet vastgelegd | In 1 aandoening |
| MT-TVmitochondrially encoded tRNA-Val (GUN) | Niet vastgelegd | In 1 aandoening |
Hoe vaak dit voorkomt bij mensen met een van de aandoeningen van het gen, de hoogste frequentie binnen die aandoeningen, zoals de Human Phenotype Ontology dit vastlegt. Deze pagina's beschrijven kenmerken en het onderzoek erachter; het zijn geen diagnose, en over symptomen kunt u het best een arts of genetisch adviseur raadplegen.
Smallere kenmerken
Bredere kenmerken
Waar dit vandaan komt
- De Human Phenotype Ontology, release 2026-09-01: het kenmerk, de namen, de definitie en de genen die ermee verbonden zijn. Meer informatie vindt u op hpo.jax.org.
- Gegevensrelease 2026.10.16-c6eea6bf.
Eén test. Een leven lang antwoorden.
Vanaf $ 449Gratis verzending · Resultaten binnen 6–8 weken